Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Unknown 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Recurrence 4Lymphoma, Follicular 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell, Marginal Zone 2Burkitt Lymphoma 2Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32Etoposide 31venetoclax 30Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Automobiles × Lymphoid × Clear all
NCT05852717 2026-05-06

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Hoosier Cancer Research Network

Phase 2 Recruiting
32 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04089215 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04718883 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Active not recruiting
59 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell

NCT05727683 2023-02-14

CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 1 Unknown
33 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡